{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:40:40Z","timestamp":1780987240202,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merrimack"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ecl.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T18:25:31Z","timestamp":1533752731000},"page":"699-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lung and Thymic Carcinoids"],"prefix":"10.1016","volume":"47","author":[{"given":"Christine L.","family":"Hann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0003-4975(92)91139-Z","article-title":"Bronchial carcinoid tumors: a retrospective analysis of 126 patients","volume":"54","author":"Harpole","year":"1992","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.011_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib4","first-page":"807","article-title":"Typical and atypical carcinoid tumours: 20-year experience with 89 patients","volume":"50","author":"Davini","year":"2009","journal-title":"J\u00a0Cardiovasc Surg (Torino)"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.04.1202","article-title":"Neuroendocrine neoplasms of the lung: a prognostic spectrum","volume":"24","author":"Asamura","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1378\/chest.119.4.1143","article-title":"Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement","volume":"119","author":"Thomas","year":"2001","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0169-5002(02)00080-6","article-title":"Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark","volume":"37","author":"Skuladottir","year":"2002","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0022-5223(19)38842-7","article-title":"Bronchial carcinoids. Review of 124 cases","volume":"89","author":"McCaughan","year":"1985","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0039-6060(97)90090-8","article-title":"Bronchial carcinoid\u2013twenty years' experience defines a selective surgical approach","volume":"122","author":"Chughtai","year":"1997","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-117-3-209","article-title":"The Cushing syndrome induced by bronchial carcinoid tumors","volume":"117","author":"Limper","year":"1992","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jtcvs.2004.02.033","article-title":"Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity","volume":"128","author":"Athanassiadi","year":"2004","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ecl.2018.04.011_bib13","series-title":"World Health Organization classification of tumours","first-page":"73","article-title":"WHO classification of tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2015"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12022-014-9320-0","article-title":"Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors","volume":"25","author":"Pelosi","year":"2014","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1183\/13993003.01954-2015","article-title":"Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome","volume":"47","author":"Rossi","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2005-837539","article-title":"Carcinoid tumors of the lung and multimodal therapy","volume":"53","author":"Divisi","year":"2005","journal-title":"Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2265.2003.01931.x","article-title":"Octreoscan in patients with bronchial carcinoid tumours","volume":"59","author":"Granberg","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.011_bib18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.011_bib19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/JTO.0b013e31818b06e3","article-title":"The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"3","author":"Travis","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2018.04.011_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ecl.2018.04.011_bib21","series-title":"Cancer: principles & practice of oncology","article-title":"Small cell and other neuroendocrine tumors of the lung","author":"Pietanza","year":"2015"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ejcts\/ezu495","article-title":"Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group","volume":"48","author":"Filosso","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.athoracsur.2017.05.019","article-title":"External validation of a prognostic model of survival for resected typical bronchial carcinoids","volume":"104","author":"Cattoni","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ecl.2018.04.011_bib24","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.011_bib26","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.athoracsur.2010.08.080","article-title":"Is sublobar resection sufficient for carcinoid tumors?","volume":"92","author":"Yendamuri","year":"2011","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0003-4975(94)00630-P","article-title":"Carcinoid tumors of the lung: do atypical features require aggressive management?","volume":"59","author":"Marty-Ane","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ecl.2018.04.011_bib28","unstructured":"(NCCN), N.C.C.N. NCCN clinical practice guidelines in oncology: neuroendocrine tumors version 3.2017. 2017. Available at: https:\/\/www.nccn.org\/."},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.athoracsur.2013.05.047","article-title":"Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance","volume":"96","author":"Lou","year":"2013","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lungcan.2003.11.016","article-title":"Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy","volume":"44","author":"Wirth","year":"2004","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2018.04.011_bib31","first-page":"1537","article-title":"Primary carcinoid tumors of the lung: a role for radiotherapy","volume":"20","author":"Mackley","year":"2006","journal-title":"Oncology (Williston Park)"},{"issue":"10022","key":"10.1016\/j.ecl.2018.04.011_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.011_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib34","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.011_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","article-title":"Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide","volume":"21","author":"Filosso","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2008.10.025","article-title":"Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients","volume":"65","author":"Srirajaskanthan","year":"2009","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/JTO.0000000000000065","article-title":"Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report","volume":"9","author":"Forde","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib38","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"28","key":"10.1016\/j.ecl.2018.04.011_bib39","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2018.04.011_bib40","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib42","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"GEPNETs update: radionuclide therapy in neuroendocrine tumors","volume":"172","author":"van der Zwan","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.011_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ctrv.2012.06.012","article-title":"Treatment of pulmonary neuroendocrine tumours: state of the art and future developments","volume":"39","author":"Gridelli","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00259-015-3190-7","article-title":"Long-term results of PRRT in advanced bronchopulmonary carcinoid","volume":"43","author":"Mariniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"10.1016\/j.ecl.2018.04.011_bib45","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.011_bib46","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9808","key":"10.1016\/j.ecl.2018.04.011_bib48","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.011_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis","volume":"109","author":"Fazio","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ecl.2018.04.011_bib50","unstructured":"(NCCN), N.C.C.N. NCCN clinical practice guidelines in oncology. Small Cell Lung Cancer Version 1. 2018. 2017. Available at: https:\/\/www.nccn.org\/."},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.athoracsur.2009.07.097","article-title":"Management of carcinoid tumors","volume":"89","author":"Detterbeck","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.011_bib52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors","volume":"92","author":"Fjallskog","year":"2001","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.011_bib53","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.011_bib54","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000345938","article-title":"Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series","volume":"97","author":"Saranga-Perry","year":"2013","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.011_bib55","first-page":"699","article-title":"Profile of capecitabine\/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors","volume":"9","author":"Kotteas","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.011_bib57","first-page":"498","article-title":"A\u00a0retrospective study of capecitabine\/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy","volume":"14","author":"Saif","year":"2013","journal-title":"JOP"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.011_bib58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the pancreas center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ecl.2018.04.011_bib59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.011_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000472255","article-title":"Thymic neuroendocrine neoplasms: biological behaviour and therapy","volume":"105","author":"Jia","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2018.04.011_bib61","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:47Z","timestamp":1760175767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852918305231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0889852918305231"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.011","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung and Thymic Carcinoids","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}